Valuation: NovoCure Limited

Market Cap 1.99B 1.74B 1.6B 1.49B 2.83B 190B 2.87B 19.21B 7.47B 93.24B 7.48B 7.32B 321B P/E 2026 *
-10.8x
P/E 2027 * -14.4x
Enterprise Value 1.77B 1.55B 1.42B 1.33B 2.51B 169B 2.55B 17.07B 6.64B 82.85B 6.64B 6.5B 285B EV / Sales 2026 *
2.51x
EV / Sales 2027 * 2.57x
Free-Float
89.99%
Yield 2026 *
-
Yield 2027 * -
1 day+9.00%
1 week+14.29%
Current month+13.53%
1 month+8.72%
3 months+63.03%
6 months+31.10%
Current year+33.02%
1 week 14.96
Extreme 14.955
17.31
1 month 13.43
Extreme 13.43
18.39
Current year 9.82
Extreme 9.82
18.92
1 year 9.82
Extreme 9.82
18.92
3 years 9.82
Extreme 9.82
42.69
5 years 9.82
Extreme 9.82
195.78
10 years 5.95
Extreme 5.95
232.76
Manager TitleAgeSince
Chief Executive Officer 46 01/12/2025
Director of Finance/CFO 52 01/01/2025
Chief Tech/Sci/R&D Officer - 17/01/2023
Director TitleAgeSince
Director/Board Member 59 01/01/2012
Chairman 63 01/01/2009
Director/Board Member 64 05/08/2011
Date Insider Type Main position Quantity % Market Cap.
06-30Free

Director

268 0.0002%
06-30Free

Chief Executive Officer

1,905 0.0016%
06-30Free

General Counsel

1,299 0.0011%
Change 5-day change 1-year change 3-year change Capi.($)
+9.00%+14.29%-3.80%-58.55% 1.99B
+0.14%+0.37%+27.56%-7.41% 12.53B
+2.20%+6.68%+71.77%+37.46% 6.23B
+1.56%+5.29%+7.24%+11.92% 5.77B
+2.63%+9.63% - - 4.38B
-0.16%+3.36%-35.35%+9.50% 4.05B
+1.60%+1.95%-25.47%-26.09% 3.85B
+1.43%+4.40%+30.75%+241.52% 1.85B
+0.94%+0.54%+58.74%-5.50% 1.54B
+1.73%+5.24%-13.60%-48.53% 1.28B
Average +2.20%+3.30%+13.09%+17.15% 4.35B
Weighted average by Cap. +1.71%+2.86%+18.30%+10.42%

Financials

2026 *2027 *
Net sales 704M 615M 566M 527M 1B 67.02B 1.01B 6.79B 2.64B 32.95B 2.64B 2.59B 114B 774M 677M 622M 580M 1.1B 73.7B 1.12B 7.47B 2.9B 36.23B 2.91B 2.84B 125B
Net income -183M -160M -147M -137M -260M -17.45B -264M -1.77B -687M -8.58B -688M -673M -29.56B -136M -119M -109M -102M -193M -12.94B -196M -1.31B -510M -6.36B -510M -499M -21.92B
Net Debt -222M -194M -178M -166M -315M -21.14B -320M -2.14B -832M -10.39B -833M -815M -35.8B -
Logo NovoCure Limited
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Employees
1,605
Date Price Change Volume
02/07/26 $17.20 +9.00% 1,953,473
01/07/26 $15.78 +4.16% 1,351,505
30/06/26 $15.15 -2.13% 1,412,328
29/06/26 $15.48 +0.32% 1,106,480
26/06/26 $15.43 +2.52% 3,294,090
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
17.20USD
Average target price
26.00USD
Spread / Average Target
+51.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVCR Stock